Product Code: RP-ID-10082826 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10082826
Market Overview:
Anal Fissure Treatment Market Analysis by Treatment Type (Laxatives, Calcium Channel Blocking Drugs, Nitroglycerin, Stool Softeners, Botulinum Toxin A, Surgery, and Others); by Route of Administration (Topical, and Oral); by End-Users (Hospitals, Clinics, Academic & Research Institutes, Homecare, Specialty Clinics, and Others); and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)-Global Supply & Demand Analysis & Opportunity Outlook 2023- 2035
Definition of Anal Fissure Treatment
Anal fissure is a tear in the skin of the anal canal which causes extreme pain in the anal canal. Anal fissures generally increase from the anal opening. They are predominantly ascribed to fecal bacteria, constipation or by protract diarrhea. Anal fissures are extremely frequent in growing children and new born infants but can affect people of any age. Mostly anal fissures get better with simple treatment, such as, increased fiber intake or sitz bath. It can be caused due to extreme physical activity or any accident.
Global Anal Fissure Treatment Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~7% |
|
Regional Scope |
|
Anal Fissure Treatment Market Highlights Over 2023- 2035
The global anal fissure treatment market is estimated to garner considerable revenue by the end of 2031 by growing at a CAGR of ~7% over the forecast period, i.e., 2022 – 2035. The growth of the market can be attributed to the expanding pediatric and geriatric patient pool with a high incidence of constipation. According to data published by the United Nations, the aging population is growing at the highest rate compared to other age groups, from around 10% in 2019 to over 15% by 2031.
GET A SAMPLE COPY OF THIS REPORT
Anal fissures are quite common, occurring in about 110 people for every 100,000. It is a tear in the thin, moist tissue (mucosa) that lines the anus. It may occur due to the passing of hard or large stools. Anal fissures cause pain, bleeding, and discomfort during bowel movements. There may be spasms in the ring of muscles at the end of the anus (anal sphincter). Most anal fissures get better with simple treatments such as increased fiber intake or sitz baths. Some people with anal fissures may recover with the help of medication, but an acute anal fissure may require the employment of lateral internal sphincterotomy (LIS), which is found to be very effective compared to other means of cure. This upward trend in surgical treatment for anal fissures is projected to drive market growth during the forecast period.
Global Anal Fissure Treatment Market: Growth Drivers and Challenges
Growth Drivers
-
High Incidence of Constipation - Straining during bowel movements and passing hard stools increases the risk of tearing and causing anal fissures. Patients with a history of constipation tend to have more frequent episodes of this condition. According to a study conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 16 out of 100 adults suffer from constipation, while 33 out of 100 adults aged 60 and above experience constipation symptoms.
-
Adoption of Unhealthy Lifestyle Choices – A diet that is not rich in fruits and vegetables is one of the major reasons for constipation which then leads to anal fissures. Chronic constipation can also be due to dehydration, stress, inadequate exercise, certain medications (strong painkillers, antidepressants), and other life activities that lead to one ignoring the urge to complete a bowel movement. According to the World Health Organization (WHO), 1 in 4 adults do not reach the global recommended levels of physical activity.
-
Advancement in Medical Technology – The use of anoscopy, sigmoidoscopy, and colonoscopy for the diagnosis of anal fissures and the increasing use of laser in treatment have created a growth in the anal fissure treatment market. Lateral Internal Sphincterotomy (LIS) is a surgical procedure where the fissure is treated by cutting or stretching the muscles around the anus. It has been estimated that around 17 million colonoscopies are performed each year in the United States.
-
Increase in Geriatric Population – According to the United States Census Bureau, the Asian elderly population (aged 65 and above) was 414 million in 2020 and is projected to rise by the year 2060 to become more than 1.2 billion.
Challenges
-
Side-Effects of Nitroglycerin Include Severe Headaches- Adverse effect of the medicine on the health of people is likely to hinder the market growth.
-
Lateral Internal Sphincterotomy (LIS) May Cause Incontinence
-
High Cost of Surgeries
The global anal fissure treatment market is segmented and analyzed for demand and supply by route of administration into oral and topical. Oral medications include laxatives, calcium channel blockers, pain-relieving agents, and stool softeners; and topical treatments include botulinum toxin A and nitroglycerin. Oral treatment options are expected to attain the highest share of the market during the forecast period as most of these medications are easily available over the counter. Laxatives are oral medicines that are widely used to treat constipation in children. With functional constipation prevalent in over 30% of children worldwide, the market for oral medications is anticipated to acquire a greater size during the forecast period.
Global Anal Fissure Treatment Market Regional Synopsis
Regionally, the global anal fissure treatment market is categorized into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Amongst these, the market in North America is projected to hold the largest share by the end of 2031 because of its growing geriatric population. According to the Administration for Community Living, people aged 65 years and above represented 16% of the US population in 2019 and is projected to be 21.6% by 2040. On the other hand, adoption of a sedentary lifestyle and increased consumption of saturated and trans-food are all major reasons for the growth of the anal fissure treatment market in the region.
Asia-Pacific has the fastest growing market due to the presence of a large number of generic manufacturers, growing awareness about anorectal diseases, and advancements in technology with new products being launched by pharmaceutical and biotechnological industries every year. As reported by the National Investment Promotion & Facilitation Agency, the pharmaceutical industry in India produced around 60,000 generic brands, including generic drugs, OTC medicines, API/bulk drugs, and others across 60 therapeutic segments.
Source – Kenneth Research
Market Segmentation
Our in-depth analysis of the anal fissure treatment market includes the following segments:
|
By Treatment Type |
|
|
By Route of Administration |
|
|
By End-user |
|
|
By Distribution Channel |
|
Key Companies Dominating the Global Anal Fissure Treatment Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the anal fissure treatment market that are included in our report are AstraZeneca, SLA Pharma AG, Eisai Co., Ltd., Bayer AG, Novasep, Ipsen Pharma, Cipla Inc., SRS Life Sciences, Healthy Life Pharma Private Limited, Geri-Care Pharmaceuticals Corp., and others.
Global Anal Fissure Treatment Market: Latest Developments
-
November 29, 2018: Eisai Co., Ltd. and Mochida Pharmaceutical Co., Ltd. launched MOVICOL HD for the treatment of chronic constipation in Japan. It is recommended for children of 2 years and above and adults.
-
January 15, 2021: Ipsen announced that a large proportion of patients treated with its Dysport (abobotulinumtoxinA) didn’t require retreatment in five therapeutic indic
- AstraZeneca
- SLA Pharma AG
- Eisai Co.Ltd.
- Bayer AG
- Novasep
- Ipsen Pharma
- Cipla Inc.
- SRS Life Sciences
- Healthy Life Pharma Private Limited
- Geri-Care Pharmaceuticals Corp
Related Reports
Proof of Quality & Reliability
